Therapeutic method to overcome basal cell carcinoma resistance
This technology is a therapeutic method utilizing bromodomain-containing proteins to treat drug-resistant basal cell carcinomas (BCCs).
Unmet Need: Limited treatment options for basal cell carcinomas due to drug resistance
Basal cell carcinomas (BCCs) are a prevalent form of malignant skin cancer; genetic conditions such as basal cell nevus syndrome (BCNS) and Gorlin-Goltz syndrome promote the uncontrolled growth of BCCs. BCCs are commonly treated with FDA-approved Smoothened (SMO) inhibitors, including vismodegib or sonidegib. However, drug resistance is extremely common, limiting the effectiveness of treatment options for patients.
The Technology: Therapeutic strategy for restoring Smoothened (SMO) inhibitor effectiveness
This technology is a therapeutic that combines the use of BRD7 and BRD9 inhibitors to treat basal cell carcinomas (BCCs) that were previously resistant to FDA-approved Smoothened (SMO) inhibitors. Bromodomain-containing proteins are identified as dysregulated in drug-resistant BCCs. By modulating protein levels, the potency of BCC to SMO inhibitors is restored, significantly increasing efficiency in BCC treatment options and combination therapies.
Applications:
- Restoration of SMO inhibitor sensitivity
- Targets for drug discovery
- Research and design method for other basal cell carcinoma (BCC) biomarkers
- Research and design method for Hedgehog (Hh) signaling-related cancers
Advantages:
- Improved effectiveness in BCC treatment
- Various administration methods
- Combination drug therapy options
- Localized site-specific delivery
Lead Inventor:
Patent Information:
Patent Pending
Tech Ventures Reference:
IR CU17184
Licensing Contact: Sara Gusik